AARD (Aardvark Therapeutics) Marketable Securities: $28.76 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $6.26
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Marketable Securities?

Aardvark Therapeutics AARD +5.12% 12 Marketable Securities is $28.76 Mil as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Aardvark Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $28.76 Mil.

Aardvark Therapeutics's annual Marketable Securities increased from Dec. 2023 ($0.25 Mil) to Dec. 2024 ($12.02 Mil) and increased from Dec. 2024 ($12.02 Mil) to Dec. 2025 ($62.98 Mil).

Aardvark Therapeutics  (NAS:AARD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Aardvark Therapeutics Marketable Securities Related Terms

Aardvark Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics Marketable Securities Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.55 0.25 12.02 62.98

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.76 115.82 87.07 62.98 28.76
AARD
12GF Score
Aardvark Therapeutics Inc AARD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $28.76 Mil mean?
Aardvark Therapeutics (AARD) has a Marketable Securities of $28.76 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Aardvark Therapeutics and its competitors.
Is Aardvark Therapeutics' Marketable Securities too high?
Aardvark Therapeutics' current Marketable Securities is $28.76 Mil. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' Marketable Securities compare to KLRS and VANI?
Aardvark Therapeutics' Marketable Securities of $28.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Aardvark Therapeutics and its competitors. Aardvark Therapeutics's current Marketable Securities is $28.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current Marketable Securities of $28.76 Mil. The current Marketable Securities is $28.76 Mil. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current Marketable Securities is $28.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.26
Price